ES2285251T3 - Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. - Google Patents

Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. Download PDF

Info

Publication number
ES2285251T3
ES2285251T3 ES03798175T ES03798175T ES2285251T3 ES 2285251 T3 ES2285251 T3 ES 2285251T3 ES 03798175 T ES03798175 T ES 03798175T ES 03798175 T ES03798175 T ES 03798175T ES 2285251 T3 ES2285251 T3 ES 2285251T3
Authority
ES
Spain
Prior art keywords
pyridylmethylphthalazine
derivative
vitamin
treatment
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03798175T
Other languages
English (en)
Spanish (es)
Inventor
Margaret Han Dugan
Alan List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
University of Arizona
Arizona's Public Universities
Original Assignee
Novartis AG
University of Arizona
Arizona's Public Universities
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, University of Arizona, Arizona's Public Universities filed Critical Novartis AG
Application granted granted Critical
Publication of ES2285251T3 publication Critical patent/ES2285251T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES03798175T 2002-09-24 2003-09-23 Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. Expired - Lifetime ES2285251T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
US413176P 2002-09-24

Publications (1)

Publication Number Publication Date
ES2285251T3 true ES2285251T3 (es) 2007-11-16

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03798175T Expired - Lifetime ES2285251T3 (es) 2002-09-24 2003-09-23 Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors

Also Published As

Publication number Publication date
AU2003299065B2 (en) 2006-10-26
JP2006502195A (ja) 2006-01-19
US20060128716A1 (en) 2006-06-15
ATE359789T1 (de) 2007-05-15
ECSP055700A (es) 2005-08-11
CN1684684A (zh) 2005-10-19
NO20051936L (no) 2005-06-23
RU2005112711A (ru) 2006-02-27
CR7754A (es) 2005-12-02
DE60313344D1 (de) 2007-05-31
PL374696A1 (en) 2005-10-31
WO2004028542A1 (en) 2004-04-08
ZA200502212B (en) 2006-02-22
CN100372535C (zh) 2008-03-05
DE60313344T2 (de) 2008-01-03
CA2499738A1 (en) 2004-04-08
HRP20050281A2 (en) 2006-07-31
BR0314647A (pt) 2005-08-02
EP1545534A1 (en) 2005-06-29
MXPA05003161A (es) 2005-09-12
EP1545534B1 (en) 2007-04-18
KR20050074450A (ko) 2005-07-18
RS20050228A (sr) 2007-08-03
AU2003299065A1 (en) 2004-04-19
RU2353364C2 (ru) 2009-04-27
PT1545534E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
ES2384789T3 (es) Combinación de un análogo de epotilona y agentes quimioterapéuticos para el tratamiento de enfermedades proliferativas
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP2012515184A (ja) 大腸がんの治療方法
ES2946472T3 (es) Agente antitumoral y potenciador del efecto antitumoral
BRPI0807232A2 (pt) Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina
US20110082101A1 (en) Combinations comprising epothilones and anti-metabolites
ES2333348T3 (es) Combinaciones que comprenden epotilonas e inhibidores de la proteina tirosina quinasa y usos farmaceuticos de las mismas.
TW202313039A (zh) Pm14用途與方案
ES2326264T3 (es) Combinacion que comprende un inhibidor de transduccion de señal y un derivado epotilona.
ES2267841T3 (es) Uso de una derivado de alfa-halogeno-acriloil distamicina para la preparacion de un medicamento para el tratamiento del cancer.
CN103391782A (zh) 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物
ES2285251T3 (es) Uso de derivados 4-piridilmetilftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.
US6822001B2 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
JPWO2013137433A1 (ja) ３剤を組み合わせた新規な抗腫瘍剤
US20090233939A1 (en) Treatment of amm
JP5503528B2 (ja) 癌の処置に寄与する方法および組成物
JP2025532720A (ja) 腫瘍血管破壊用医薬組成物
AU2007200677B2 (en) Combinations comprising epothilones and anti-metabolites
JP2006502195A5 (enExample)
WO2008033039A1 (en) Cancer treatment